drugset / Trial / NCT04656600

Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ

NCT04656600

Phase 4 Completed 12 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective * To evaluate the efficacy on hematologic manifestations of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the safety profile of imiglucerase in maximum dose in the label (60U/kg, IV biweekly) in Chinese patients. Secondary Objective * To evaluate the efficacy on viscera manifestations of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the efficacy on bone disease of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the effect on quality of life of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ

Timeline

Start
2021-03-02
Primary completion
2023-10-12
Completion
2023-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiglucerase Protein / enzyme biologic 60 iu/kg Intravenous